Marburg, Germany – 2 June 2026 – CSL (ASX:CSL), a global biopharma leader, today announced that the European Commission has granted marketing authorisation for Privigen®, a human immunoglobulin (IG) therapy indicated for pre- and post-exposure prophylaxis to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended.
The approval comes at a critical time. Health authorities across Europe, including the European Centre for Disease Prevention and Control, reported a sharp increase in measles cases in 2024. In 2025, case numbers remained elevated, with reported infections approximately twice as high as in 2023.[1][2]
“While vaccination remains the most effective way to prevent measles, outbreaks across Europe highlight the urgent need for additional tools to protect those at risk,” said Emmanuelle Lecomte Brisset, Head Global Regulatory Affairs and Safety at CSL. “This approval ensures clinicians have access to an immunoglobulin option where passive protection may be considered.”
Privigen is a ready-to-use human immunoglobulin prepared from screened donor plasma and is indicated to provide pre- and post-exposure prophylaxis for susceptible high-risk individuals, including immunocompromised patients, pregnant women without evidence of immunity, and infants or other vulnerable contacts with high unmet needs, for whom active immunization is contraindicated or not recommended.
It is supported by a well-established safety profile based on clinical use and long‑term real‑world experience with immunoglobulin therapies.
Immunoglobulin therapy works by providing concentrated antibodies that can neutralise the measles virus after exposure and may provide passive antibody protection following exposure. This makes immunoglobulin therapy a potential option for individuals who cannot rely on vaccination or require prompt prophylactic support following exposure.
European approval is based on strong clinical and real-world evidence supporting the safety and efficacy of Privigen for the approved use in preventing measles and protecting high-risk patients.
About Privigen®
Privigen® is the first and only 10%, ready-to-use, human liquid intravenous immunoglobulin stabilised with proline, a naturally occurring amino acid, with purity of at least 98% immunoglobulin G. Privigen® was first approved in 2007 in the U.S. In Europe, beyond the measles indication, it is approved for adults, children and adolescents as an immunoglobulin replacement therapy for the treatment of patients with primary immunodeficiency and secondary immunodeficiencies, as well as for immunomodulatory treatment in chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, Kawasaki disease and multifocal motor neuropathy. Privigen® is available in more than 60 countries worldwide for the treatment of these and other rare diseases. For more information about Privigen®, visit: CSL.com
About Measles
Measles is a highly contagious viral illness spread through respiratory droplets. Despite the availability of effective vaccines, measles continues to cause outbreaks when vaccination rates fall below the level required for herd immunity. Public health authorities recommend maintaining high vaccination coverage to prevent transmission and protect vulnerable populations.
About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor - provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.
Media Contact:
Bernadette Murdoch
Martin Wans
[1] European Centre for Disease Prevention and Control “Community spread drives ongoing measles transmission in Europe” 9 February 2026 https://www.ecdc.europa.eu/en/news-events/community-spread-drives-ongoing-measles-transmission-europe Accessed 23 February 2026
[2] World Health Organization “Measles” 28 November 2025 https://www.who.int/news-room/fact-sheets/detail/measles Accessed 23 February 2026
